ArticleInternational journal of nanomedicine2018
In vitro/vivo drug release and anti-diabetic cardiomyopathy properties of curcumin/PBLG-PEG-PBLG nanoparticles.
Article in International journal of nanomedicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 29 citations in OpenAlex.
- Current State of Scientific Knowledge on Curcumin Encapsulation and Applications.Recent advances in food, nutrition & agriculture · 2025Review
- Role of polyphenolic compounds and their nanoformulations: a comprehensive review on cross-talk between chronic kidney and cardiovascular diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Therapeutic Applications of Curcumin in Diabetes: A Review and Perspective.BioMed research international · 2022Review
- Molecular prospect of type-2 diabetes: Nanotechnology based diagnostics and therapeutic intervention.Reviews in endocrine & metabolic disorders · 2021Review
- Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases.International journal of nanomedicine · 2021Review
- An Updated Insight Into Molecular Mechanism of Hydrogen Sulfide in Cardiomyopathy and Myocardial Ischemia/Reperfusion Injury Under Diabetes.Frontiers in pharmacology · 2021Review
- Nanostructured Polymeric, Liposomal and Other Materials to Control the Drug Delivery for Cardiovascular Diseases.Pharmaceutics · 2020Review
- Plant-Based Antidiabetic Nanoformulations: The Emerging Paradigm for Effective Therapy.International journal of molecular sciences · 2020Review
- Anti-inflammatory Effect of Curcumin, Homotaurine, and Vitamin D3 on Human Vitreous in Patients With Diabetic Retinopathy.Frontiers in neurology · 2020Article
- Exogenous hydrogen sulfide protects against high glucose-induced apoptosis and oxidative stress by inhibiting the STAT3/HIF-1α pathway in H9c2 cardiomyocytes.Experimental and therapeutic medicine · 2019Article
- Nanoformulations of natural products for management of metabolic syndrome.International journal of nanomedicine · 2019Review
Corrections and comments
- Retraction · 2021-05-25Duplication of/in Image · Error in Image · Unreliable Data · · see also: https://pubpeer.com/publications/78B9CF77368453B0CB4627E90D1EA9
- Retracted
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe objective of this study was to survey the therapeutic function of curcumin-encapsulated poly(gamma-benzyl l-glutamate)-poly(ethylene glycol)-poly(gammabenzyl l-glutamate) (PBLG-PEG-PBLG) (P) on diabetic cardiomyopathy (DCM) via cross regulation effect of calcium-sensing receptor (CaSR) and endogenous cystathionine-γ-lyase (CSE)/hydrogen sulfide (H
methodsDiabetic rats were preconditioned with 20 mg/kg curcumin or curcumin/P complex continuously for 8 weeks. The blood and myocardiums were collected, the level of serum H
resultsBoth curcumin and curcumin/P pretreatment alleviated pathological morphological damage of myocardium, increased H
conclusionPBLG-PEG-PBLG could improve water-solubility and bioactivity of curcumin and curcumin/PBLG-PEG-PBLG significantly alleviated diabetic cardiomyopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.